Gamma Knife surgery for patients with brainstem metastases.

Takuya Kawabe, Masaaki Yamamoto, Yasunori Sato, Bierta E. Barfod, Yoichi Urakawa, Hidetoshi Kasuya, Katsuyoshi Mineura

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Because brainstem metastases are not deemed resectable, stereotactic radiosurgery (SRS) is the only treatment modality expected to achieve a radical cure. The authors describe their treatment results, focusing particularly on how long patients can survive without neurological deterioration following SRS for brainstem metastases. This was an institutional review board-approved, retrospective cohort study in which the authors pulled from their database information on 2553 consecutive patients with brain metastases who underwent Gamma Knife surgery (GKS) at the Mito GammaHouse between July 1998 and July 2011. Among the 2553 patients, excluding cases in which there was meningeal dissemination, 200 cases of brainstem metastases (78 women and 122 men with a mean age of 64 years [range 36-86 years]) were identified and analyzed. The most common primary site was the lung (137 patients) followed by the gastrointestinal tract (24 patients), breast (17 patients), kidney (12 patients), and others (10 patients). Among the 200 patients, 15 patients (7.5%) harbored at least 2 tumors in the brainstem: 11 patients had 2 tumors, 2 patients had 3 tumors, and 1 patient each had 4 or 5 tumors. Therefore, a total of 222 tumors were irradiated. These 222 tumors were located in the pons (121 lesions), the midbrain (65 lesions), and the medulla oblongata (36 lesions). The mean and median tumor volumes were 1.3 and 0.2 cm(3) (range 0.005-10.7 cm(3)), and the median peripheral radiation dose was 18.0 Gy (range 12.0-25.0 Gy). The overall median survival time (MST) was 6.0 months. Distribution of MSTs across Recursive Partitioning Analysis (RPA) classes showed that the MSTs were 9.4 months in Class I (20 patients), 6.0 months in Class II (171 patients), and 1.9 months in Class III (9 patients). Better Karnofsky Performance Scale score, single metastasis, and well-controlled primary tumor were significant predictive factors for longer survival. The neurological and qualitative survival rates were 90.8% and 89.2%, respectively, at 24 months post-GKS. Better KPS score and smaller tumor volume tended to be associated with prolonged qualitative survival. Follow-up imaging studies were available for 129 patients (64.5%). The tumor control rate was 81.8% at 24 months post-GKS. Smaller tumor volume tended to contribute to tumor control. The present results indicate that GKS is effective in the treatment of brainstem metastases, particularly from the viewpoint of maintaining a good neurological condition in the patient.

Original languageEnglish
Pages (from-to)23-30
Number of pages8
JournalJournal of neurosurgery
Volume117 Suppl
Publication statusPublished - 2012 Jan 1
Externally publishedYes

Fingerprint

Brain Stem
Neoplasm Metastasis
Neoplasms
Tumor Burden
Radiosurgery
Survival
Brain Stem Neoplasms
Karnofsky Performance Status
Medulla Oblongata
Pons
Research Ethics Committees
Mesencephalon
Gastrointestinal Tract

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Cite this

Kawabe, T., Yamamoto, M., Sato, Y., Barfod, B. E., Urakawa, Y., Kasuya, H., & Mineura, K. (2012). Gamma Knife surgery for patients with brainstem metastases. Journal of neurosurgery, 117 Suppl, 23-30.

Gamma Knife surgery for patients with brainstem metastases. / Kawabe, Takuya; Yamamoto, Masaaki; Sato, Yasunori; Barfod, Bierta E.; Urakawa, Yoichi; Kasuya, Hidetoshi; Mineura, Katsuyoshi.

In: Journal of neurosurgery, Vol. 117 Suppl, 01.01.2012, p. 23-30.

Research output: Contribution to journalArticle

Kawabe, T, Yamamoto, M, Sato, Y, Barfod, BE, Urakawa, Y, Kasuya, H & Mineura, K 2012, 'Gamma Knife surgery for patients with brainstem metastases.', Journal of neurosurgery, vol. 117 Suppl, pp. 23-30.
Kawabe T, Yamamoto M, Sato Y, Barfod BE, Urakawa Y, Kasuya H et al. Gamma Knife surgery for patients with brainstem metastases. Journal of neurosurgery. 2012 Jan 1;117 Suppl:23-30.
Kawabe, Takuya ; Yamamoto, Masaaki ; Sato, Yasunori ; Barfod, Bierta E. ; Urakawa, Yoichi ; Kasuya, Hidetoshi ; Mineura, Katsuyoshi. / Gamma Knife surgery for patients with brainstem metastases. In: Journal of neurosurgery. 2012 ; Vol. 117 Suppl. pp. 23-30.
@article{b956a4a7643b425593aab3565e774370,
title = "Gamma Knife surgery for patients with brainstem metastases.",
abstract = "Because brainstem metastases are not deemed resectable, stereotactic radiosurgery (SRS) is the only treatment modality expected to achieve a radical cure. The authors describe their treatment results, focusing particularly on how long patients can survive without neurological deterioration following SRS for brainstem metastases. This was an institutional review board-approved, retrospective cohort study in which the authors pulled from their database information on 2553 consecutive patients with brain metastases who underwent Gamma Knife surgery (GKS) at the Mito GammaHouse between July 1998 and July 2011. Among the 2553 patients, excluding cases in which there was meningeal dissemination, 200 cases of brainstem metastases (78 women and 122 men with a mean age of 64 years [range 36-86 years]) were identified and analyzed. The most common primary site was the lung (137 patients) followed by the gastrointestinal tract (24 patients), breast (17 patients), kidney (12 patients), and others (10 patients). Among the 200 patients, 15 patients (7.5{\%}) harbored at least 2 tumors in the brainstem: 11 patients had 2 tumors, 2 patients had 3 tumors, and 1 patient each had 4 or 5 tumors. Therefore, a total of 222 tumors were irradiated. These 222 tumors were located in the pons (121 lesions), the midbrain (65 lesions), and the medulla oblongata (36 lesions). The mean and median tumor volumes were 1.3 and 0.2 cm(3) (range 0.005-10.7 cm(3)), and the median peripheral radiation dose was 18.0 Gy (range 12.0-25.0 Gy). The overall median survival time (MST) was 6.0 months. Distribution of MSTs across Recursive Partitioning Analysis (RPA) classes showed that the MSTs were 9.4 months in Class I (20 patients), 6.0 months in Class II (171 patients), and 1.9 months in Class III (9 patients). Better Karnofsky Performance Scale score, single metastasis, and well-controlled primary tumor were significant predictive factors for longer survival. The neurological and qualitative survival rates were 90.8{\%} and 89.2{\%}, respectively, at 24 months post-GKS. Better KPS score and smaller tumor volume tended to be associated with prolonged qualitative survival. Follow-up imaging studies were available for 129 patients (64.5{\%}). The tumor control rate was 81.8{\%} at 24 months post-GKS. Smaller tumor volume tended to contribute to tumor control. The present results indicate that GKS is effective in the treatment of brainstem metastases, particularly from the viewpoint of maintaining a good neurological condition in the patient.",
author = "Takuya Kawabe and Masaaki Yamamoto and Yasunori Sato and Barfod, {Bierta E.} and Yoichi Urakawa and Hidetoshi Kasuya and Katsuyoshi Mineura",
year = "2012",
month = "1",
day = "1",
language = "English",
volume = "117 Suppl",
pages = "23--30",
journal = "Journal of Neurosurgery",
issn = "0022-3085",
publisher = "American Association of Neurological Surgeons",

}

TY - JOUR

T1 - Gamma Knife surgery for patients with brainstem metastases.

AU - Kawabe, Takuya

AU - Yamamoto, Masaaki

AU - Sato, Yasunori

AU - Barfod, Bierta E.

AU - Urakawa, Yoichi

AU - Kasuya, Hidetoshi

AU - Mineura, Katsuyoshi

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Because brainstem metastases are not deemed resectable, stereotactic radiosurgery (SRS) is the only treatment modality expected to achieve a radical cure. The authors describe their treatment results, focusing particularly on how long patients can survive without neurological deterioration following SRS for brainstem metastases. This was an institutional review board-approved, retrospective cohort study in which the authors pulled from their database information on 2553 consecutive patients with brain metastases who underwent Gamma Knife surgery (GKS) at the Mito GammaHouse between July 1998 and July 2011. Among the 2553 patients, excluding cases in which there was meningeal dissemination, 200 cases of brainstem metastases (78 women and 122 men with a mean age of 64 years [range 36-86 years]) were identified and analyzed. The most common primary site was the lung (137 patients) followed by the gastrointestinal tract (24 patients), breast (17 patients), kidney (12 patients), and others (10 patients). Among the 200 patients, 15 patients (7.5%) harbored at least 2 tumors in the brainstem: 11 patients had 2 tumors, 2 patients had 3 tumors, and 1 patient each had 4 or 5 tumors. Therefore, a total of 222 tumors were irradiated. These 222 tumors were located in the pons (121 lesions), the midbrain (65 lesions), and the medulla oblongata (36 lesions). The mean and median tumor volumes were 1.3 and 0.2 cm(3) (range 0.005-10.7 cm(3)), and the median peripheral radiation dose was 18.0 Gy (range 12.0-25.0 Gy). The overall median survival time (MST) was 6.0 months. Distribution of MSTs across Recursive Partitioning Analysis (RPA) classes showed that the MSTs were 9.4 months in Class I (20 patients), 6.0 months in Class II (171 patients), and 1.9 months in Class III (9 patients). Better Karnofsky Performance Scale score, single metastasis, and well-controlled primary tumor were significant predictive factors for longer survival. The neurological and qualitative survival rates were 90.8% and 89.2%, respectively, at 24 months post-GKS. Better KPS score and smaller tumor volume tended to be associated with prolonged qualitative survival. Follow-up imaging studies were available for 129 patients (64.5%). The tumor control rate was 81.8% at 24 months post-GKS. Smaller tumor volume tended to contribute to tumor control. The present results indicate that GKS is effective in the treatment of brainstem metastases, particularly from the viewpoint of maintaining a good neurological condition in the patient.

AB - Because brainstem metastases are not deemed resectable, stereotactic radiosurgery (SRS) is the only treatment modality expected to achieve a radical cure. The authors describe their treatment results, focusing particularly on how long patients can survive without neurological deterioration following SRS for brainstem metastases. This was an institutional review board-approved, retrospective cohort study in which the authors pulled from their database information on 2553 consecutive patients with brain metastases who underwent Gamma Knife surgery (GKS) at the Mito GammaHouse between July 1998 and July 2011. Among the 2553 patients, excluding cases in which there was meningeal dissemination, 200 cases of brainstem metastases (78 women and 122 men with a mean age of 64 years [range 36-86 years]) were identified and analyzed. The most common primary site was the lung (137 patients) followed by the gastrointestinal tract (24 patients), breast (17 patients), kidney (12 patients), and others (10 patients). Among the 200 patients, 15 patients (7.5%) harbored at least 2 tumors in the brainstem: 11 patients had 2 tumors, 2 patients had 3 tumors, and 1 patient each had 4 or 5 tumors. Therefore, a total of 222 tumors were irradiated. These 222 tumors were located in the pons (121 lesions), the midbrain (65 lesions), and the medulla oblongata (36 lesions). The mean and median tumor volumes were 1.3 and 0.2 cm(3) (range 0.005-10.7 cm(3)), and the median peripheral radiation dose was 18.0 Gy (range 12.0-25.0 Gy). The overall median survival time (MST) was 6.0 months. Distribution of MSTs across Recursive Partitioning Analysis (RPA) classes showed that the MSTs were 9.4 months in Class I (20 patients), 6.0 months in Class II (171 patients), and 1.9 months in Class III (9 patients). Better Karnofsky Performance Scale score, single metastasis, and well-controlled primary tumor were significant predictive factors for longer survival. The neurological and qualitative survival rates were 90.8% and 89.2%, respectively, at 24 months post-GKS. Better KPS score and smaller tumor volume tended to be associated with prolonged qualitative survival. Follow-up imaging studies were available for 129 patients (64.5%). The tumor control rate was 81.8% at 24 months post-GKS. Smaller tumor volume tended to contribute to tumor control. The present results indicate that GKS is effective in the treatment of brainstem metastases, particularly from the viewpoint of maintaining a good neurological condition in the patient.

UR - http://www.scopus.com/inward/record.url?scp=84873280064&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873280064&partnerID=8YFLogxK

M3 - Article

C2 - 23205785

AN - SCOPUS:84873280064

VL - 117 Suppl

SP - 23

EP - 30

JO - Journal of Neurosurgery

JF - Journal of Neurosurgery

SN - 0022-3085

ER -